BioNexus Gene Lab Corp Common stock (BGLC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioNexus Gene Lab Corp Common stock (BGLC) has a cash flow conversion efficiency ratio of -0.181x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.23 Million) by net assets ($6.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BioNexus Gene Lab Corp Common stock (BGLC) balance sheet quality index to measure how much of total assets are equity-financed.
BioNexus Gene Lab Corp Common stock - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how BioNexus Gene Lab Corp Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BioNexus Gene Lab Corp Common stock earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
BioNexus Gene Lab Corp Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioNexus Gene Lab Corp Common stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kedaung Indah Can Tbk
JK:KICI
|
-0.009x |
|
Bounty Oil & Gas NL
AU:BUY
|
-0.034x |
|
Mid Wynd International Investment Trust plc
LSE:MWY
|
0.002x |
|
Canadian Spirit Resources Inc
V:SPI
|
-0.024x |
|
SKRR Exploration Inc
V:SKRR
|
-0.077x |
|
Tempest Minerals Ltd
AU:TEM
|
0.034x |
|
Oriental Culture Holding Ltd
NASDAQ:OCG
|
0.009x |
|
Wilmington PLC
LSE:WIL
|
0.018x |
Annual Cash Flow Conversion Efficiency for BioNexus Gene Lab Corp Common stock (2016–2024)
The table below shows the annual cash flow conversion efficiency of BioNexus Gene Lab Corp Common stock from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see BGLC company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.32 Million | $-2.23 Million | -0.268x | -47.24% |
| 2023-12-31 | $9.66 Million | $-1.76 Million | -0.182x | -323.36% |
| 2022-12-31 | $6.67 Million | $544.03K | 0.082x | +6297.18% |
| 2021-12-31 | $7.18 Million | $9.16K | 0.001x | -98.46% |
| 2020-12-31 | $6.66 Million | $552.68K | 0.083x | +142.85% |
| 2019-12-31 | $1.12 Million | $-217.27K | -0.194x | -7.49% |
| 2018-12-31 | $1.52 Million | $-274.08K | -0.180x | -104.77% |
| 2017-12-31 | $94.63K | $357.22K | 3.775x | +492.70% |
| 2016-12-31 | $-1.31K | $-835.00 | 0.637x | -- |
About BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; a… Read more